Helixmith Co., Ltd.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1996-01-01
- Employees
- 75
- Market Cap
- -
- Website
- http://helixmith.com
Clinical Trials
21
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (20 trials with phase data)• Click on a phase to view related trials
The Efficacy and Safety of TADIOS as an Adjuvant Therapy in Patients Diagnosed With Mild to Moderate COVID-19
- Conditions
- COVID-19
- Interventions
- Drug: PlaceboDrug: TADIOS
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05552625
- Locations
- 🇮🇳
Vagus Super Specialty Hospital, Bangalore, Karnataka, India
🇮🇳Sparsh Superspeciality Hospital, Bangalore, Karnataka, India
🇮🇳Lakshmi Nursing Home, Cochin, Kerala, India
The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)
- Conditions
- CMT
- Interventions
- Biological: Engensis (VM202)
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05361031
- Locations
- 🇰🇷
Samsung Medical Center, Seoul National University Hospital, Seoul, Korea, Republic of
A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Other: Placebo
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT05176093
- Locations
- 🇺🇸
Austin Neuromuscular Center, Austin, Texas, United States
🇰🇷Hanyang University Medical Center, Seoul, Korea, Republic of
A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
- Conditions
- Diabetic Peripheral Neuropathy
- Interventions
- Other: Placebo
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 106
- Registration Number
- NCT04873232
- Locations
- 🇺🇸
Arizona Research Center, Phoenix, Arizona, United States
🇺🇸Clinical Trials - Little Rock, Little Rock, Arkansas, United States
🇺🇸California Medical Clinic for Headache, Los Angeles, California, United States
Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Other: Placebo
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04632225
- Locations
- 🇺🇸
St. Joseph's Hospital and Medical Center, Barrows Neurological Institute, Phoenix, Arizona, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Johns Hopkins University Department of Neurology, Baltimore, Maryland, United States
- Prev
- 1
- 2
- 3
- 4
- Next